Plant-based Vaccines Market to Grow USD 2.0 Billion by 2027
The global Plant-based Vaccines market gathered revenue around USD 1.20 Billion in 2020 and market is set to grow USD 2.0 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 7.0% during the prediction period 2021 to 2027.
Plant-based vaccines offer several benefits over conventional egg-based vaccine production, in terms of efficiency, production time, and enhancing immune system of the patient. For instance, Medicago's quadrivalent influenza vaccine (QIV) is produced using novel virus-like particle (VLP) technology, which offers new approach in vaccine development and production. In VLP technology, vaccine mimics the native structure of viruses, allowing them to easily get penetrated into patient’s immune system. However, this QIV vaccine lacks core genetic material, rendering them to become non-infectious and unable to replicate. This enables plant-based vaccine to be safe and highly effective to induce immune response of patient similar to natural infection without infecting the patient.
However, various plant-based vaccines are currently in clinical trial phase I, II, and III. Several plant-based vaccines have been developed in various transgenic plants such as insulin in transgenic safflower, taliglucerase alfa in transgenic carrot, avian influenza vaccine in transgenic tobacco, Ebola vaccine in transgenic tobacco, among others. However, there is no plant-derived vaccine approved to be marketed for human consumption to date. Moreover, some of the challenges to develop highly effective vaccines from downstream processing to the implementation of the vaccines include: selection of antigen and plant expression host, uniformity of dosage, and manufacturing of plant vaccines according to Good Manufacturing Practice (GMP) procedures
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Plant-based Vaccines market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Plant-based Vaccines market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Plant-based Vaccines market report empower readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
| Report Highlights | Details |
| Market Size | US$ 2.0 Billion by 2027 |
| Growth Rate | CAGR of 7.0% From 2021 to 2027 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2027 |
| Segments Covered | Type, Plant Source, Application ,Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | Creative Biolabs, Medicago Inc., iBio, Fraunhofer Center for Manufacturing Innovation, ICON, EEA Consulting Engineers, Protalix, and Kentucky BioProcessing, Inc. |
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Some of the prominent players in the Plant-based Vaccines Market include: Creative Biolabs, Medicago Inc., iBio, Fraunhofer Center for Manufacturing Innovation, ICON, EEA Consulting Engineers, Protalix, and Kentucky BioProcessing, Inc.
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
Plant-based Vaccines Market, by Type
Plant-based Vaccines Market, by Plant Source
Plant-based Vaccines Market, by Application
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Highlights of the Report:
Research Methodology
In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Plant-based Vaccines market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the Plant-based Vaccines market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Plant-based Vaccines markets more accurate and reliable.
Secondary Research
It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.
The secondary research sources referred in the process are as follows:
Primary Research
Primary research includes face-to face interviews, online surveys, and telephonic interviews.
Industry participants involved in this research study include:
Key Points Covered in Plant-based Vaccines market Study:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Plant-based Vaccines Market, By Type
7.1. Plant-based Vaccines Market, by Type, 2021-2027
7.1.1. Bacterial Vaccine
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Viral Vaccine
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Others
7.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global Plant-based Vaccines Market, By Plant Source
8.1. Plant-based Vaccines Market, by Plant Source, 2021-2027
8.1.1. Tobacco
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Potato
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Plant-based Vaccines Market, By Application
9.1. Plant-based Vaccines Market, by Application, 2021-2027
9.1.1. Against Infectious Agents
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Anti-cancer
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Against Autoimmune Disorders
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global Plant-based Vaccines Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2016-2027)
10.1.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.1.3. Market Revenue and Forecast, by Application (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.1.4.3. Market Revenue and Forecast, by Application (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.1.5.3. Market Revenue and Forecast, by Application (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.2.3. Market Revenue and Forecast, by Application (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.2.4.3. Market Revenue and Forecast, by Application (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.2.5.3. Market Revenue and Forecast, by Application (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.2.6.3. Market Revenue and Forecast, by Application (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Type (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.2.7.3. Market Revenue and Forecast, by Application (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.3.3. Market Revenue and Forecast, by Application (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.3.4.3. Market Revenue and Forecast, by Application (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.3.5.3. Market Revenue and Forecast, by Application (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.3.6.3. Market Revenue and Forecast, by Application (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Type (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.3.7.3. Market Revenue and Forecast, by Application (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.4.3. Market Revenue and Forecast, by Application (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.4.4.3. Market Revenue and Forecast, by Application (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.4.5.3. Market Revenue and Forecast, by Application (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.4.6.3. Market Revenue and Forecast, by Application (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Type (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.4.7.3. Market Revenue and Forecast, by Application (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.5.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.5.3. Market Revenue and Forecast, by Application (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Type (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.5.4.3. Market Revenue and Forecast, by Application (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Type (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Plant Source (2016-2027)
10.5.5.3. Market Revenue and Forecast, by Application (2016-2027)
Chapter 11. Company Profiles
11.1. Creative Biolabs
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Creative Biolabs
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. iBio
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Fraunhofer Center for Manufacturing Innovation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. ICON
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. EEA Consulting Engineers
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Protalix
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Kentucky BioProcessing, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers